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objectives were to 1) develop a simulation model which can simulate QoL and differ-
ent cost categories from a societal perspective as affected by AS treatments with 
sequential drugs using the ASAS recommendations at group level; 2) parameterize the 
model using Dutch data; and 3) analyze simulated cost-effectiveness of treatment 
strategies with and without anti-TNFs. METHODS: Discrete-event paradigm was 
selected for model development. Pathways in AS treatments were simulated in conjunc-
tion with changes in AS-speciﬁ c measures. Parameterization was realized using original 
data from an observational cohort of AS patients and literature where necessary. 
Frequencies of visits to rheumatologists and hospitals, and having paramedical treat-
ments, informal/formal care, sick leave, and work disability were estimated using logit 
and Poisson regression models. Health utility was estimated using a proportional-odds 
model. Demographic variables were also considered in model selections. Two com-
pared strategies in the simulation were 1) three Cox-1 plus two Cox-2 selective 
nonsteroidal anti-inﬂ ammatory drugs, and 2) same as strategy 1 plus Etanercept and 
Inﬂ iximab. The simulation was run for 1000 patients until death. RESULTS: Simu-
lated values of QALYs and different cost categories were in reasonable ranges. Pro-
ductivity and hospital costs constituted largest shares of the total costs, and were 
signiﬁ cantly lower in strategy 2 (P < 0.05). The incremental cost per QALY gained of 
strategy 2 against strategy 1 was c25,165. CONCLUSIONS: The model is ﬂ exible and 
promising for assessing actual costs-effectiveness of different treatment strategies for 
different societies. 
PODIUM SESSION II: IRT AND RACH MODELING IN QUALITY OF 
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OBJECTIVES: To evaluate a new standardized disease-speciﬁ c PRO impact item bank, 
the Kidney Disease Impact Scale (KDIS), among adults with chronic kidney disease 
(CKD). METHODS: A 34-item bank of items measuring disease impact, with stan-
dardized content (differing only in disease attribution) and standardized IRT-based 
parameters from previous studies across therapeutic areas, was administered to 516 
CKD patients, along with CKD-speciﬁ c legacy (KDQOL Effects and Burden scales) 
and a generic (SF-12v2) health survey. All measures were administered in a clinic 
setting at three time points (baseline, 1 week, and 3 months) to evaluate: 1) reliability 
(internal consistency and 1-week test–retest); 2) validity in discriminating among CKD 
groups differing in clinically deﬁ ned disease severity (nondialysis stages 3–5, dialysis 
patients, and transplant patients); and 3) responsiveness (better, same, or worse after 
3 months). Real-data CAT simulations were performed, using only the responses to 
items that would have been selected and asked during a real CAT, to estimate KDIS 
scores based on the full bank, and 5-, 10-, and 15-item CATs. RESULTS: As hypoth-
esized, CAT-based score distributions were less skewed and estimates were more 
efﬁ cient (covered a wider range and were as reliable with fewer items), in comparison 
with legacy measures. All KDIS forms (full bank, various lengths of CATs) discrimi-
nated among clinically deﬁ ned groups as well or better than legacy CKD-speciﬁ c 
measures and correlated substantially with generic HRQOL measures. Relative valid-
ity (RV) coefﬁ cients for discriminant validity and responsiveness tests for 1-minute 
(5-item) CAT-based administrations compared favorably with scores based on the 
entire bank (RV = 0.84), KDQOL scores (RV = 0.79 for Burden and 0.50 for Effects), 
and generic measures (RV = 0.00 to 0.59, median = 0.13). CONCLUSIONS: Disease-
speciﬁ c PROs can be improved to be more practical and more valid, in comparison 
with legacy CKD-speciﬁ c and generic PROs. CKD impact measures that perform better 
psychometrically tend to perform better in empirical tests of clinical validity.
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OBJECTIVES: The DLQI is a 10-item generic dermatological HRQoL measure used 
widely with psoriasis patients. The PSORIQoL is a 25-item psoriasis-speciﬁ c measure 
that employs the needs-based model of quality of life (QoL). Both measures have been 
shown to have good psychometric properties using Classical Test Theory. However, 
their scaling properties have not been fully assessed using Item Response Theory (IRT). 
This is the purpose of the study. METHODS: Psoriasis patients, recruited from an 
out-patients clinic, completed the DLQI and PSORIQoL. IRT (Rasch analysis) was 
used to determine each measure’s overall ﬁ t to the Rasch model, individual item ﬁ t, 
targeting of scales to severity of respondents, functioning of response categories, and 
the presence of Differential Item Functioning (DIF) by age or gender. RESULTS: 146 
psoriasis patients were included in the study (male 50%, mean age = 44.2, range = 
17–83 years). DLQI: There was overall misﬁ t to the Rasch model (χ2 = 39.85, df = 
20, P = 0.005). One item misﬁ t the Rasch model and another showed borderline misﬁ t. 
Four of the 10 items had disordered response thresholds indicating that they did not 
work in a logical way. Too few DLQI items covered milder levels of HRQoL (meaning 
that the measure is not sensitive to change in patients with mild disease). DIF by age 
was found in one item and DIF by gender in another. PSORIQoL: Overall, the measure 
ﬁ t the Rasch model (χ2 = 56.45, df = 50, P = 0.247), although one item had a high 
ﬁ t residual suggesting misﬁ t. The response options worked logically and items were 
well distributed across the QoL measurement range. No DIF by age or gender was 
found. CONCLUSIONS: Application of Rasch analysis indicated that there were 
several problems with the scaling properties of the DLQI. In contrast, the PSORIQoL 
ﬁ t the Rasch model and exhibited good measurement properties.
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OBJECTIVES: This study aims to provide sample-free estimates of uniform DIF on a 
newly developed HRQL questionnaire, PROQOL-HIV, based on IRT. Patient char-
acteristics considered here were gender, country of residence, and ethnicity, given the 
high prevalence of HIV in migrant populations. METHODS: We use a two-step 
ordinal logistic regression to test for the signiﬁ cance of person covariates, on two 
constructs extracted from factor analysis: Physical Health and Symptoms (PHS, 14 
items), and Emotional distress and Health Concerns (EDHC, 10 items). a subset of N 
= 505 patients (71% males, median age 43 years) from ﬁ ve countries (Australia, United 
States, France, Brazil, and Thailand) was used. Person parameters were estimated 
using a Graded Response Model. Missing responses (<1%) were imputed using half-
rule. RESULTS: The EDHC dimension was more prone to exhibit item biases com-
pared to PHS items, especially when referring to ethnicity. Country-related effects were 
equally distributed on the two scales. In both cases, however, no DIF effects were 
found for gender. We reached similar conclusions when comparing the results to those 
obtained when using sum or rest scores as conditioning ability levels. Correlations 
between raw scores computed with or without ﬂ agged items were above 0.5. Restrict-
ing analyses to Western countries, however, yielded smaller hits. Altogether, these 
results suggest that DIF effects should be of limited impact when reporting scores for 
these two HRQL dimensions of the PROQOL-HIV questionnaire. Results are dis-
cussed in light of other latent variable models proposed to assess DIF, the MIMIC, 
and logistic mixed effects model. CONCLUSIONS: Using IRT instead of summated 
scale scores allows the incorporation of person covariates and the study of DIF effects 
in a probabilistic framework. The presence of DIF effects on biopsychological con-
structs raises important cross-cultural validity considerations for multi-country multi-
ethnic studies, although assessment of DIF impact needs further investigations.
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OBJECTIVES: No speciﬁ c health-related quality of life (HRQOL) instrument tool is 
available for Huntington’s disease (HD). In the context of a large European study on 
HD burden (Euro-HDB), a speciﬁ c HRQoL tool (HQOLI) was created for patients in 
early and intermediate stages of HD. We describe the development and psychometric 
validation of HQOLI. METHODS: After semistructured interviews with patients, 
caregivers, and HD specialists, we ran a patient focus group. a self-reported question-
naire was then devised in French language. The questionnaire consists of 42 items, 
relating to 11 dimensions: Mobility, Motor Ability, Autonomy 1 and 2, Finance, 
Occupational Activities, Psychology, Feelings of Guilt, Vitality, Socializing, and Body 
Image. Face validity and internal and external validity were examined. RESULTS: 
Among 178 participating patients, 15 did not complete HQOLI. Item response rates 
range from 0.81 to 0.98, excluding the occupational activities domain. As expected, 
there is a ceiling effect on several items, suggesting low sensitivity at advanced HD 
stage. Cronbach’s alphas are greater than 0.76. HQOLI total score is highly correlated 
with generic HR-QOL (SF36 and EQ5D) as well as with the speciﬁ c caregiver HRQoL 
instrument (HDQoL-C). Correlations were −0.73 (P < 0.01) with EQ5D utility, −0.76 
(P < 0.01) with “Physical Functioning,” and −0.74 (P < 0.01) with “Mental Health.” 
Voluntary movement, fall/balance, and dystonia symptoms contribute signiﬁ cantly to 
HQOLI (P = 0.01), but chorea does not (P = 0.21). CONCLUSIONS: These data 
support the validity of the HQOLI in patients with HD. The ceiling effect limits the 
use of HQOLI in late stages but appears necessary to achieve good discrimination at 
early and intermediate stages. Correlations with other instruments suggest good exter-
nal validity. High correlations of several items within dimensions suggest item number 
can be reduced. a new, shorter version of the questionnaire is in development. Assess-
ments of responsiveness to change, test–retest reliability, and cross-cultural validation 
will be performed/are underway. 
